Repositori URV

Identificador: imarina:5128778

Handle: https://hdl.handle.net/20.500.11797/imarina5128778

Autores:
Frentz, DinekeVan de Vijver, David A M CAbecasis, Ana BAlbert, JanHamouda, OsamahJorgensen, Louise BKucherer, ClaudiaStruck, DanielSchmit, Jean-ClaudeVercauteren, JurgenAsjo, BirgittaBalotta, ClaudiaBeshkov, DanailCamacho, Ricardo JClotet, BonaventuraCoughlan, SuzieGriskevicius, AlgirdasGrossman, ZehavaHorban, AndrzejKolupajeva, TatjanaKorn, KlausKostrikis, Leondios GLiitsola, KirsiLinka, MarekNielsen, ClausOtelea, DanParaskevis, DimitriosParedes, RogerPoljak, MarioPuchhammer-Stockl, ElisabethSonnerborg, AndersStanekova, DanicaStanojevic, MajaVan Wijngaerden, EricWensing, Annemarie M JBoucher, Charles A BSPREAD Programme

Resumen:
Background: One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program.Methods: Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy.Results: The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations remained constant at 5%, a significant decline in protease inhibitors resistance mutations was observed, from 3.9% in 2002 to 1.6% in 2007 (p = 0.001). In contrast, resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) doubled from 2.0% in 2002 to 4.1% in 2007 (p = 0.004) with 58% of viral strains carrying a K103N mutation. Phylogenetic analysis showed that these temporal changes could not be explained by large clusters of TDRM.Conclusion: During the years 2002 to 2007 transmitted resistance to NNRTI has doubled to 4% in Europe. The frequent use of NNRTI in first-line regimens and the clinical impact of NNRTI mutations warrants continued monitoring.